checkAd
    Startseite > Aktien > NKGen Biotech > Nachrichten
    NKGen Biotech Aktie
    1,1500
     
    USD
    -7,26 %
    -0,0900 USD
    Letzter Kurs 02:00:00 NYSE
    1,1300
     
    USD
    700 STK
    Geldkurs 14.05.24
    1,1600
     
    USD
    100 STK
    Briefkurs 14.05.24
    ISIN: US65488A1016 · WKN: A3EQS7 · SYM: NKGN · USA

    Neueste Nachrichten

    NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson’s Disease
    29.04.24 · globenewswire · NKGen Biotech
    NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit
    25.04.24 · globenewswire · NKGen Biotech
    NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    24.04.24 · globenewswire · NKGen Biotech
    NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit
    18.04.24 · globenewswire · NKGen Biotech
    NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs
    11.04.24 · globenewswire · NKGen Biotech
    NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference
    25.03.24 · globenewswire · NKGen Biotech
    NKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer’s Disease at the Tau2024 Global Conference
    04.03.24 · globenewswire · NKGen Biotech
    NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer’s Disease
    28.12.23 · globenewswire · NKGen Biotech
    NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease
    27.12.23 · globenewswire · NKGen Biotech
    NKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights
    14.11.23 · globenewswire · NKGen Biotech
    NKGen Biotech Presented Phase I Clinical Trial Data at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
    26.10.23 · globenewswire · NKGen Biotech
    NKGen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease
    24.10.23 · globenewswire · NKGen Biotech